Report Date: Tuesday, August 4, 2026, before market open | Conference call 8:00 a.m. ET
Henry Schein shares have had a strong run into this print, rallying from the low-$70s in May to roughly $86-87 currently — near the stock's highs for the year and just below the average analyst price target of $89.31. The stock's momentum reflects a solid Q1 beat, reaffirmed full-year guidance, and generally constructive sellside sentiment (consensus rating skews Buy), but it also raises the bar for what the market will consider "good enough" tomorrow.
Henry Schein delivered a clean beat in Q1: first quarter 2026 GAAP net income was $107 million or $0.92 per diluted share, compared with prior year GAAP net income of $110 million or $0.88 per diluted share, while first quarter 2026 non-GAAP net income was $153 million or $1.32 per diluted share, compared to prior year non-GAAP net income of $143 million or $1.15 per diluted share. That non-GAAP EPS figure beat the Street's estimate by roughly 10%, and revenue of $3.37 billion also came in ahead of the $3.34 billion consensus.
Growth was driven by U.S. dental and global technology, offsetting medical softness. Sales strengthened in the U.S. dental and global technology businesses, it overcame softness in the medical business, with the quarter impacted by a decline in demand for point-of-care diagnostic test products related to respiratory illness, resulting from a light flu season. Management reiterated that trends improved sequentially, noting looking at the quarter sequentially, we saw better performance sequentially through the quarter. So March was stronger than February... even that continued in April. So April continues to be strong — a helpful read-through into Q2.
Management reaffirmed full-year 2026 guidance: 2026 non-GAAP diluted EPS is unchanged and expected to be $5.23 to $5.37, and 2026 total sales growth is unchanged and expected to be approximately 3% to 5% over 2025, with Adjusted EBITDA expected to grow mid-single digits compared with 2025.
1. Dental market health & DSO share gains. New CEO Fred Lowery (now ~5 months into the job) has been consistent that the dental market remains healthy with demand continuing to outpace supply, and that the U.S. we think there was a slightly more positive tone to the market, still relatively low market growth, but our data indicates that we are taking market share there. Watch for continued commentary on DSO strength (DSOs have a strong position with all the national DSOs...and they're growing faster) and whether intraoral scanner/3D printer price deflation continues to weigh on digital equipment growth even as unit volumes rise.
2. Value creation / cost program cadence. The company is mid-way through a multi-year restructuring effort targeting greater than $200 million of annual operating income improvement within the next few years with $125 million run rate by the end of 2026. Management explicitly guided that savings would build through the year: we're going to start seeing that savings begin to accelerate as we get into the second quarter and then even more so in the third and the fourth quarter. Q2 is the first quarter where investors should start seeing tangible margin benefit — a miss here would raise questions about the back-half ramp needed to hit full-year EPS guidance.
3. Cost inflation — oil, freight, tariffs. Management flagged rising oil prices as a swing factor for freight costs and glove/PPE input costs, but expressed confidence it could be managed: we have implemented a number of measures designed to offset the potential financial impact of rising oil prices... guidance assumes that we can mitigate rising [costs], but there's a tipping point out there. Given oil prices have stayed elevated, this is worth monitoring for gross margin commentary.
4. Leadership transition and org restructuring. On July 30, Henry Schein announced it is replacing its Executive Management Committee with a new "Henry Schein Leadership Team" and integrating global supply chain into its distribution group, with three long-tenured executives — COO Michael Ettinger, Chief Strategy Officer Mark Mlotek, and SVP Global Supply Chain Jim Mullins — moving to senior advisory roles effective October 30, 2026. This is a continuation of the broader leadership reset following Stanley Bergman's departure and Lowery's arrival as CEO, and is framed as an effort to make the company "simpler" and faster-moving; investors will want color on integration risk and continuity.
5. KKR strategic partnership / governance overhang. Henry Schein remains under a Strategic Partnership Agreement with KKR Hawaii Aggregator L.P., which made a $250 million private placement investment in 2025 and holds board seats (KKR-designated directors Max Lin and Dan Daniel, the latter now Independent Board Chairman as of May 2026). KKR recently exercised its extension election, keeping its board influence intact through 2027 — a reminder that capital allocation, buybacks (still ~$655 million authorized as of Q1) and further portfolio/JV consolidation moves remain influenced by this relationship.
6. Specialty/implants recovery. Premium implant softness (flat-to-down, more pronounced in the U.S. than Europe) was a Q1 sore spot even as value implants grew high-single digits; management guided to improved specialty growth as the year progresses — worth checking for confirmation.
Henry Schein heads into Q2 with reaffirmed guidance, sequential business momentum cited through April, and a stock that has already re-rated meaningfully higher over the past two months — leaving less room for error. The print will be as much about execution proof points (cost-savings ramp, gross margin trajectory, specialty recovery) and organizational stability amid a fresh round of leadership changes as it is about the headline EPS/revenue beat-or-miss against the ~$1.22 consensus.